Trial Profile
Comparison of one-year non-persistence rates between direct oral anticoagulants (dabigatran or rivaroxaban) and vitamin K antagonists in patients with newly treated nonvalvular atrial fibrillation: A French Nationwide cohort study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Sep 2017
Price :
$35
*
At a glance
- Drugs Dabigatran etexilate (Primary) ; Rivaroxaban (Primary) ; Vitamin K antagonists
- Indications Embolism and thrombosis
- Focus Adverse reactions
- 20 Sep 2017 New trial record
- 30 Aug 2017 Results presented at the 33rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management